https://doi.org/10.4081/monaldi.2026.3802
Atherogenic dyslipidemia as a novel cardiovascular risk stratification tool in chronic obstructive pulmonary disease: a hospital-based cross-sectional study
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 6 August 2026
Chronic obstructive pulmonary disease (COPD) is characterized by progressive airway obstruction and systemic inflammation, frequently accompanied by metabolic comorbidities, including dyslipidemia. The Atherogenic Index of Plasma (AIP), calculated as log10[triglycerides/high-density lipoprotein (HDL)-cholesterol], is strongly associated with atherosclerotic cardiovascular disease risk, yet its relationship with COPD-associated dyslipidemia remains underexplored. This study investigates the association between atherogenic dyslipidemia profiles and COPD duration, utilizing AIP as an evaluation metric. A hospital-based cross-sectional analytical study was conducted among 100 COPD patients without acute exacerbations. Fasting serum lipid profiles were analyzed using standardized protocols, and AIP was calculated for each participant. Patients were stratified into three AIP risk categories: low risk (AIP<0.21), moderate risk (AIP 0.21-0.5), and high risk (AIP>0.5). Associations between COPD duration, smoking status, demographic variables, and lipid parameters were examined using chi-square analysis. 60% of COPD patients demonstrated high atherogenic index profiles (AIP>0.5), indicating substantial cardiovascular risk. A significant positive correlation was found between COPD duration and AIP (r=0.456, p<0.001), as well as with triglycerides (r=0.341, p<0.001) and low-density lipoprotein-cholesterol (r=0.405, p<0.001). Conversely, COPD duration demonstrated a nonsignificant trend toward an inverse correlation with HDL-cholesterol (r=-0.173, p=0.089). Seventy-one percent of patients demonstrated low HDL-cholesterol (<40 mg/dL). Smoking status was significantly associated with elevated very low-density lipoprotein-cholesterol (p=0.002). The high prevalence of atherogenic dyslipidemia in COPD patients, as quantified by AIP, suggests that lipid profile alteration is progressive and correlates with disease duration. AIP represents a clinically relevant, cost-effective screening tool for identifying COPD patients at elevated cardiovascular risk, facilitating early intervention and personalized risk stratification strategies.
Downloads
GOLD. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2024 Report. Available from: https://goldcopd.org/2024-gold-report/.
Vicol C, Buculei I, Melinte OE, et al. The lipid profile and biochemical parameters of COPD patients in relation to smoking status. Biomedicines 2022;10:2936. DOI: https://doi.org/10.3390/biomedicines10112936
GOLD. 2026 GOLD Report and Pocket Guide - Global Initiative for Chronic Obstructive Lung Disease. Available from: https://goldcopd.org/2026-gold-report-and-pocket-guide/.
Xuan L, Han F, Gong L, et al. Association between chronic obstructive pulmonary disease and serum lipid levels: a meta-analysis. Lipids Health Dis 2018;17:263. DOI: https://doi.org/10.1186/s12944-018-0904-4
Sarkar GC, Paul SK, Chakrabortty R, et al. Lipid profile patterns in chronic obstructive pulmonary disease and its correlation with the severity of disease. Bangabandhu Sheikh Mujib Medical University J 2022;15:37-41. DOI: https://doi.org/10.3329/bsmmuj.v15i4.64151
Liu D, Meister M, Zhang S, et al. Identification of lipid biomarker from serum in patients with chronic obstructive pulmonary disease. Respir Res 2020;21:242. DOI: https://doi.org/10.1186/s12931-020-01507-9
Šebeková K, Gurecká R, Csongová M, Koborová I, Celec P. Association of Atherogenic Index of Plasma with Cardiometabolic Risk Factors and Markers in Lean 14-to-20-Year-Old Individuals: A Cross-Sectional Study. Children 2023;10:1144. DOI: https://doi.org/10.3390/children10071144
Dobiášová M, Frohlich J. The plasma parameter log(TG/HDL-C) as an atherogenic index: Correlation with lipoprotein particle size and esterification rate inapo B-lipoprotein particles in diabetic and non-diabetic subjects. Clin Biochem 2001;34:583-8. DOI: https://doi.org/10.1016/S0009-9120(01)00263-6
Bao Z, Zhang Y, Zhou J, Dai Z. Association between atherogenic index of plasma and infertility: a cross-sectional study based on U.S. women. Lipids Health Dis 2025;24:51. Erratum in: Lipids Health Dis 2025;24:104. DOI: https://doi.org/10.1186/s12944-025-02469-x
Wang Y, Wang S, Sun S, et al. The predictive value of atherogenic index of plasma for cardiovascular outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention with LDL-C below 1.8mmol/L. Cardiovasc Diabetol 2023;22:150. DOI: https://doi.org/10.1186/s12933-023-01888-3
Niroumand S, Khajedaluee M, Khadem-Rezaiyan M, et al. Atherogenic Index of Plasma (AIP): A marker of cardiovascular disease. Med J Islam Repub Iran 2015;29:240.
Karimpour Reyhan S, Yadegar A, Samimi S, et al. Atherogenic Index of Plasma (AIP): the most accurate indicator of overweight and obesity among lipid indices in type 2 diabetes-findings from a cross-sectional study. Endocrinol Diabetes Metab 2024;7:e70007. DOI: https://doi.org/10.1002/edm2.70007
Maury J, Gouzi F, De Rigal P, et al. Heterogeneity of systemic oxidative stress profiles in COPD: a potential role of gender. Oxid Med Cell Longev 2015;2015: 201843. DOI: https://doi.org/10.1155/2015/201843
Arora S, Jain R, Mohan A, et al. Lipid profile status in chronic obstructive pulmonary disease and its association with disease severity. Int Journal of Respir Pulmon Med 2018;5:089. DOI: https://doi.org/10.23937/2378-3516/1410089
Zafirova-Ivanovska B, Stojkovikj J, Dokikj D, et al. The level of cholesterol in COPD patients with severe and very severe stage of the disease. Open Access Maced J Med Sci 2016;4:277-82. DOI: https://doi.org/10.3889/oamjms.2016.063
Jungck D, Stadler S, Krasney JA, Voelkel NF. HDL serum levels are significantly lower in patients with COPD than in never-smokers. Chest 2009;136:52S.
Rafie S, Moitra S, Brashier BB. Association between the serum metabolic profile and lung function in chronic obstructive pulmonary disease. Turk Thorac J 2017;19:13-8. DOI: https://doi.org/10.5152/TurkThoracJ.2017.17043
Khojah HM, Ahmed SA. Comparative assessment of individual RONS in serum of smokers compared with non-smokers and their correlation with the lipid profile and antioxidant status. J Int Med Res 2019;47:6223-34. DOI: https://doi.org/10.1177/0300060519882563
Mamoshina P, Kochetov K, Cortese F, et al. Blood biochemistry analysis to detect smoking status and quantify accelerated aging in smokers. Sci Rep 2019;9:142. DOI: https://doi.org/10.1038/s41598-018-35704-w
National Cholesterol Education Program (NCEP) ATP III. (2001). National institutes of health: at-a-glance. Avaialable from: https://www.nhlbi.nih.gov/files/docs/guidelines/atglance.pdf.
Ethics Approval
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.